Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.81 |
| ▸ | RAB9A | P51151 | 5/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | TP53 | P04637 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | GOT1 | P17174 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | MPO | P05164 | 2/20 | 0.81 |
| ▸ | MAOA | P21397 | 2/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.81 |
| ▸ | PKM | P14618 | 1/20 | 0.81 |
| ▸ | THPO | P40225 | 1/20 | 0.81 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.81 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydralazine SCHEMBL2779489 | 0.92 | NPC1 (0.73) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL15140051 | 0.91 | NPC1 (0.71) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL2783124 | 0.91 | NPC1 (0.71) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL3995896 | 0.90 | ALDH1A1 (1.00) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL7810 | 0.90 | ALDH1A1 (1.00) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL2780318 | 0.88 | ALDH1A1 (0.89) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL27864907 | 0.88 | GOT1 (1.00) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL1173534 | 0.88 | GOT1 (1.00) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL36271 | 0.88 | GOT1 (1.00) | NPC1RAB9AALDH1A1LMNAKDM4E | |
| Hydralazine SCHEMBL5671747 | 0.88 | NPC1 (0.76) | NPC1RAB9AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130197038-A1 | Compositions And Methods For Neovascularization | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-01 | — | — | US | claimed |
| US-9446031-B2 | Compositions and methods for neovascularization | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-09-20 | — | — | US | disclosed |
| US-20130197038-A1 | Compositions And Methods For Neovascularization | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-01 | — | — | US | disclosed |
| US-7728133-B2 | Stable pharmaceutical compositions | B&G PARTNERS LLC | 2010-06-01 | — | — | US | disclosed |
| EP-1480649-A4 | STABLE PHARMACEUTICAL COMPOSITIONS | BARBEAU DONALD L (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050130975-A1 | Stable pharmaceutical compositions | B&G PARTNERS LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1480649-A2 | STABLE PHARMACEUTICAL COMPOSITIONS | Barbeau, Donald L. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6825196-B2 | SUCH AS 1-HYDRAZINOPHTHALAZINE; METAL-FREE | BARBEAU PHARMA, INC. | 2004-11-30 | — | — | US | disclosed |
| US-6821974-B2 | VASODILATION; HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | BARBEAU PHARMA, INC | 2004-11-23 | — | — | US | disclosed |
| US-20030212272-A1 | Stable pharmaceutical compositions | B&G PARTNERS LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030199512-A1 | Stable pharmaceutical compositions | BARBEAU PHARMA INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003075928-A2 | STABLE PHARMACEUTICAL COMPOSITIONS | BARBEAU DONALD L (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130975-A1 | Stable pharmaceutical compositions | CYP3A7, NR1H2, CYP2B6 | NPC1 386/4885RAB9A 1607/4885ALDH1A1 1633/4885 |
| US-20030199512-A1 | Stable pharmaceutical compositions | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HBZ, HRH1 | NPC1 583/4885RAB9A 1189/4885ALDH1A1 446/4885 |
| US-20030212272-A1 | Stable pharmaceutical compositions | CYP3A7, ARL1, ATXN2L | NPC1 441/4885RAB9A 540/4885ALDH1A1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.